Page 256 - Drug Class Review
P. 256
Page 158 of 205
Drug Effectiveness Review Project
Groups similar at baseline: Yes, although 10 percentage point difference in sex
placebo 72.9 59 100 19.26 29.77 4.16 11.78 Primary Outcome Measures: GBS total score plus the 4 domains: GBS-I (intellectual), GBS-ADL No significant differences in GBS-ADL, GBS-E, or GBS-S subtotals at endpoint Treatment response to DON was not predicted by APOE genotype or sex Significantly slower decline in PDS total score for DON-treated patients (P < 0.05); specific differences noted on telephone use (P < 0.01), memory (P < 0.01), and self care (P < 0.05) Significantly slower decline in MMSE for DON-treated patients (P < 0.001) Significantly slower decline
Alzheimer classification: Mild-moderate
Health Outcome Measures: Outcome Measures: 0.054)
donepezil 72.1 69.7 100 19.37 29.51 4.15 13.05 (activities of daily living), GBS-E (reasoning), GBS-S (behavior) Secondary Outcome Measures: MMSE; ADL; PDS; NPI; GDS Timing of assessments: Weeks 4, 12, 36 and 52 No significant differences in NPI at endpoint
• • • • • • • •
Final Report Update 1 Author: Winblad et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% white): Other germane population qualities: Mean baseline MMSE • Mean baseline GBS • Mean baseline GDS • Mean baseline NPI • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
